¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"cancer susceptibility gene"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
¿µ¹® gene ÇÑ±Û À¯ÀüÀÚ
¼³¸í   
  À¯ÀüÀڴ ±æ°Ô ¶ì¸¦ Çü¼ºÇÑ DNAºÐÀÚÀÇ ÀϺκÐÀ¸·Î ÇÑ °¡Áö ¹°ÁúÀ» ¸¸µå´Âµ¥ ÇÊ¿äÇÑ ¸ðµç Á¤º¸¸¦ °®Ãá ±â´ÉÀûÀΠ´ÜÀ§ÀÌ´Ù. ¿¹¸¦ µé¾î Àν¶¸°À̶ó´Â ¹°ÁúÀÇ À¯ÀüÀÚ¶ó°í Çϸ頻ç¶÷ÀÇ ¼¼Æ÷³»¿¡ Àִ ±ä DNA ºÐÀÚ Áß¿¡¼­ Àν¶¸°À̶ó´Â ¹°ÁúÀ» ¸¸µå´Âµ¥ ÇÊ¿äÇÑ ¸ðµç Á¤º¸¸¦ °¡Áö°í Àִ ÇÑ ºÎºÐÀ» °¡¸®Å°´Â ¸»ÀÌ´Ù. °íÀüÀûÀΠ»ý¹°Çп¡¼­´Â À¯ÀüÀÚ°¡ Ç¥ÇöÇüÀ» °áÁ¤Çϰųª ÁöÁ¤Çϴ ¿°»öüÀÇ ÀϺκÐÀ̶ó°í Á¤ÀǵǾúÁö¸¸, ¿À´Ã³¯¿¡´Â À¯ÀüÀÚ¿¡ ´ëÇØ¼­ ºÐÀÚÀû Á¤Àǰ¡ Á¦¾ÈµÇ°í ÀÖÀ¸¸ç ±× Á¤ÀǴ ÇϳªÀÇ À¯ÀüÀڴ ÇϳªÀÇ È¿¼Ò¸¦ °áÁ¤ ¶Ç´Â ¾ÏȣȭÇϴ À¯Àü¹°ÁúÀÇ ÀϺκÐÀ̶ó´Â °³³äÀ¸·Î À̰ÍÀÌ À̸¥¹Ù 1°³ÀÇ À¯ÀüÀÚ 1°³ È¿¼Ò°¡¼³(one gene-one enzyme hypothesis)ÀÌ´Ù. Áï 1°³ÀÇ À¯ÀüÀڴ 1°³ÀÇ È¿¼Ò¸¦ Á¦ÀÛÇϴµ¥ ÇÊ¿äÇÑ À¯ÀüÁ¤º¸¸¦ °¡Áø´Ù´Â °ÍÀÌ´Ù. ÇöÀç ÀÌ °¡¼³ÀÌ ¹Þ¾Æµé¿©Áö°í ÀÖ´Ù.
¿µ¹® gene therapy ÇÑ±Û À¯ÀüÀÚ¿ä¹ý
¼³¸í   
  À¯Àüº´À» Ä¡·áÇÒ ¸ñÀûÀ¸·Î, Á¤»óÀûÀ¸·Î ±â´ÉÇϴ ´ÜÀÏÀ¯ÀüÀڠȤÀº º¹¼öÀ¯ÀüÀÚ¸¦ ¾î¶² ±â¿ø¿¡¼­ ¾ò¾î³»¾î »ý¼¼Æ÷¿¡ µµÀÔÇϴ °Í. À¯Àü¹°ÁúÀº À¯ÀüÀÚ»ðÀÔ Á¶ÀÛ¿¡ ÀÇÇØ ¼ö¿ë¼¼Æ÷¿¡·Î µµÀԵȴÙ. Áï, À¯ÀüÀÚ¸¦ ³¢¿ö ³ÖÀº »õ·Î¿î ¼¼Æ÷¸¦ »ç¿ëÇϴ ġ·á·Î¼­ 1980³â ¹Ì±¹ÀÇ ÇÐÀÚ°¡ ÁöÁßÇØºóÇ÷ȯÀÚ¿¡°Ô °­ÇàÇÏ¿© ºñÆÇÀ» ¹Þ¾ÒÁö¸¸, ¹Ì±¹ ±¹¸³º¸°Ç¿¬±¸¼Ò´Â 1990³â 9¿ù ¾Æµ¥³ë½Å µ¥¾Æ¹Ì³ª¾ÆÁ¦(adenosine deaminase, ADA) °áÇÌÁõ È¯ÀÚÀÇ ¸²ÇÁ±¸¿¡ ADA À¯ÀüÀÚ¸¦ ³¢¿ö ³Ö´Â Ä¡·á¸¦ ½ÃÀÛÇÑ ÀÌ·¡ ÇöÀç´Â ¾ÏÀ» Æ÷ÇÔÇÑ ¸¹Àº Áúº´µéÀ» Ä¡·áÇϴ ¸ñÀûÀ¸·Î ¾²ÀδÙ.
¿µ¹® ovarian cancer ÇÑ±Û ³­¼Ò¾Ï
¼³¸í   
  ¿©¼ºÀÇ ³­¼Ò¿¡ ¹ß»ýÇϴ ¾Ï. ºÎÀΰúÁ¾¾çÀ¸·Î¼­ 50¼¼ À̻󠿩¼º¾Ç¼ºÁ¾¾çÀÇ ¾à 18%¸¦ Â÷ÁöÇÑ´Ù. Á¾¾çÀº ´ë°³ º¹ºÎ ±í¼÷È÷ À§Ä¡ÇϹǷΠÁ¾¾çÀÌ ¸¹ÀÌ ÁøÇàµÈ »óÅ¿¡¼­ ¹ß°ßµÇ´Â ¼ö°¡ ¸¹À¸¸ç, ¶ÇÇÑ Á¾¾çÀÇ Ãʱ⿡´Â Áõ»óÀÌ °ÅÀÇ ¾ø´Â °æ¿ì°¡ ¸¹¾Æ ´õ¿í Á¶±â¹ß°ßÀÌ ¾î·Æ´Ù.
  
  ¾ÆÁÖ ´Ù¾çÇÑ Á¾·ùÀÇ ¾ÏÀÌ ¹ß»ýÇϸç, ¿¹Èĵµ °¢±â ±× Á¾¾çÀÇ Á¾·ù¿¡ µû¶ó ´Ù¸£´Ù. ´ëÇ¥ÀûÀΠ¾ÏÀ¸·Î À强³¶»ù¾ÏÁ¾(serous cystadenocarcinoma), Á¡¾×³¶»ù¾ÏÁ¾(mucinous cystadenocarcinoma), Á¾ÀÚ¼¼Æ÷Á¾(germinoma µîÀÌ ÀÖ´Ù. Ä¡·á´Â ¼ö¼úÀû Ä¡·á°¡ ¼±ÇàµÇ¾î¾ß ÇÏÁö¸¸, ¸¹ÀÌ ÁøÇàµÇ¾î À̹̠´Ù¸¥ Á¶Á÷À¸·Î ÀüÀ̰¡ ÀÌ·ç¾îÁø »óÅ¿¡¼­´Â È­Çпä¹ýÀÌ ¼±ÅÃÀûÀ¸·Î »ç¿ëµÈ´Ù.
¿µ¹® cancer ÇÑ±Û ¾Ï
¼³¸í   
  ³¡¾øÀÌ ºÐ¿­À» ÇÏ¿© Ç÷¾×À̳ª ¸²ÇÁ°üÀ» ÅëÇÏ¿© ´Ù¸¥ Àå±â¿¡±îÁö ÀüÆÄµÉ ¼ö Àִ ¼¼Æ÷ÀÇ µ¢¾î¸®. ÁǼº ½Å»ý¹°À» ¸»ÇÑ´Ù. ½Å»ý¹°Àº ¾Ç¼º°ú ¾ç¼ºÀÌ Àִµ¥, ¾Ç¼ºÀÏ °æ¿ì¿¡´Â ¼ºÀåÀÌ ¸Å¿ì ºü¸£°í Ç÷¾×À̳ª ¸²ÇÁ°üÀ» ÅëÇØ¼­ ¸Ö¸® ´Ù¸¥ ¶³¾îÁø Àå±â·Î ¾Ï¼¼Æ÷ÀÇ ÀüÆÄ°¡ °¡´ÉÇÏ¿© ´Ù¸¥ Àå±â¿¡µµ ¾ÏÀ» ÀüÀÌÇϸç, ¾ç¼ºÀº ÃµÃµÈ÷ ÀÚ¶ó°í ´Ù¸¥°÷À¸·Î ÀüÀ̰¡ »ý±âÁö ¾Ê´Â´Ù.
  
  ¾ÏÀº ¾ÏÁ¾°ú À°Á¾ÀÇ µÎ °¡Áö·Î ³ª´­ ¼ö°¡ ÀÖ´Ù. ¾ÏÁ¾À̶õ »óÇǼ¼Æ÷ÀÇ °úµµÇÑ Áõ½Ä¿¡ ÀÇÇÑ ¾Ç¼º½Å»ý¹°À» À̸£´Â ¸»À̰í À°Á¾À̶õ ºñ»óÇǼº¼¼Æ÷ Æ¯È÷ Áß°£¿±¼¼Æ÷(¹ß»ý´ç½Ã¿¡ Áß°£¿±¿¡ ÇØ´çÇϴ Á¶Á÷À¸·Î ¹ß»ýÈÄ¿¡ Á¶Á÷»çÀÌ¿¡ ºÐÆ÷Çϸ鼭 Á¶Á÷À» ÁöÁöÇϴ ¿ªÇÒÀ» Çϴ °áÇÕÁ¶Á÷, Ç÷°ü, ¸²ÇÁ°ü µîÀÌ µÈ´Ù)ÀÇ °úµµÇÑ Áõ½Ä¿¡ ÀÇÇÑ ¾Ç¼º ½Å»ý¹°À» À̸£´Â ¸»ÀÌ´Ù.
¿µ¹® cancer surgery ÇÑ±Û ¾Ï ¼ö¼ú
¼³¸í   
  ¾ÏÀÇ 4´ë Ä¡·á¹ýÀº ¿Ü°úÀû ¼ö¼ú¿ä¹ý, ¹æ»ç¼± Ä¡·á¹ý, Ç׾ϠȭÇпä¹ý, ¸é¿ª¿ä¹ý µîÀ» ¸»Çϸç ÀÌÁß ¼ö¼ú¿ä¹ý°ú ¹æ»ç¼± ¿ä¹ýÀº ±¹¼ÒÀû ¿ä¹ýÀ¸·Î¼­ ¾Ï¼¼Æ÷°¡ ¿ø¹ßÀå±â(óÀ½ ¾ÏÀÌ ¹ß»ýÇÑ Àå±â)³ª ±¹¼Ò ¸²ÇÁÀý±îÁö ±¹ÇѵǾî Àִ Á¦ 1, 2±â ¾ÏÀÇ Ä¡·á¿¡ »ç¿ëµÈ´Ù. È­Çпä¹ý°ú ¸é¿ª¿ä¹ýÀº Àü½Å¿ä¹ýÀ¸·Î¼­ Á¦ 3, 4±â ¾Ï¿¡ ÁַΠ»ç¿ëµÇ¸ç, 1, 2±â ¾ÏÀÇ Ä¡·á ÈÄ ´«¿¡ º¸ÀÌÁö ¾Ê°Ô ³²¾Æ ÀÖÀ» ¼ö Àִ ÀÜ·ù¾Ï¼¼Æ÷³ª ¹Ì¼¼ÀüÀÌ ¾Ï¼¼Æ÷ÀÇ ¿ÏÀüÆÄ±«, »ç¸êÀ» À§ÇØ »ç¿ëµÈ´Ù. ¹éÇ÷º´, ¸²ÇÁÁ¾°ú °°ÀÌ È­Çпä¹ýÁ¦¿¡ Àß µè´Â Ç÷¾×¾Ï, ¸²ÇÁÁ¾°ú °íȯÁ¾°ú °°ÀÌ ¹æ»ç¼± Ä¡·á¿¡ Àß µè´Â ¾ÏÀ» Á¦¿ÜÇÑ ´ëºÎºÐÀÇ °íÇü¾Ï(solid tumor)ÀΠÀ§Ã¢ÀÚ°ü¾Ï, °£¾Ï, ÀÌÀÚ¾Ï, À¯¹æ¾Ï, °©»ó»ù¾Ï, Æó¾Ï, Èæ»öÁ¾, ¿¬Á¶Á÷¾Ï, »ÀÀ°Á¾, Ä§»ù¾Ï µîÀº ¸ðµÎ ¼ö¼ú¿ä¹ýÀ¸·Î Ä¡·áÇÏ¿©¾ß ÇÑ´Ù.
  
  ¾Ï¼ö¼úÀÇ ±âº»¿øÄ¢: ¾Ï¼ö¼úÀÇ 3°¡Áö ±âº»¿ä°ÇÀº ¾ÈÀü¼º, ±ÙÄ¡¼º, ±â´Éº¸Á¸¼ºÀ̸砾ϼö¼ú½Ã¿¡´Â ¾Ïº´Å͸¦ µÇµµ·Ï Á¶½ÉÇØ¼­ Àû°Ô ¸¸Áö¸é¼­ ¼ö¼úÇÏ°í ¾Ïº´Å͸¦ °ø±ÞÇϴ µ¿Á¤¸Æ°ú ¸²ÇÁ°üÀ» ¸ÕÀú °áÂûÇÏ¿© ¾Ïº´ÅͰ¡ ÆÛÁö´Â °ÍÀ» ¹æÁöÇÑ´Ù.
  
  ¾Ï¼ö¼úÀÇ ¸ñÇ¥´Â ±ÙÄ¡Àû ÀýÁ¦¼ö¼ú(radical surgery)ÀÌ´Ù. ±×·¯³ª À̰ÍÀÌ ºÒ°¡´ÉÇѠȯÀÚ¿¡¼­´Â ÃâÇ÷, Æó»ö, Ãµ°ø µîÀÇ ÇÕº´ÁõÀÌ ¹ß»ýÇßÀ»¶§ ±¸±Þ¸ñÀûÀ¸·Î È¤Àº Áö¼ÓÀû µ¿ÅëÀÌ ÀÖÀ»¶§ »ýȰ³»¿ëÀÇ ÁúÀû °³¼±À» À§ÇÏ¿© °í½ÄÀû ¼ö¼ú(palliative surgery)À» ÇÑ´Ù. ±×¸®°í ¾ÏÀÇ Á¤È®ÇÑ Áø´Ü°ú ÁøÇ൵ÀÇ °áÁ¤À» À§ÇÑ Áø´ÜÀû ¼ö¼ú(diagnostic surgery)ÀÌ ÀÖ´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • antimicrobial susceptibility
    Ç×±ÕÁ¦°¨¼ö¼º
  • antimicrobial susceptibility test
    Ç×±ÕÁ¦°¨¼ö¼º°Ë»ç
  • dynamic susceptibility contrast technique
    ¿ªµ¿ÀÚÈ­À²´ëÁ¶±â¹ý
  • disease susceptibility
    Áúº´°¨¼ö¼º
  • genetic susceptibility
    À¯ÀüÀû°¨¼ö¼º
  • hypnotic susceptibility
    Ãָ鰨¼ö¼º
  • host susceptibility
    ¼÷ÁÖ°¨¼ö¼º
  • magnetic susceptibility
    ÀڱⰨ¼öÀ², ÀÚÈ­À², ´ëÀÚÀ²
  • magnetic susceptibility artifact
    ÀÚÈ­À²Àΰø¹°
  • magnetic susceptibility gradient
    ÀÚ±âÈ­À²±â¿ï±â
  • susceptibility
    °¨¼ö¼º
  • susceptibility gradient
    °¨¼ö¼º±â¿ï±â
  • advanced cancer
    ÁøÇà¾Ï
  • anal cancer
    Ç×¹®¾Ï
  • bladder cancer
    ¹æ±¤¾Ï
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • susceptibility
    °¨¼ö¼º
  • antimicrobial susceptibility
    Ç×±ÕÁ¦°¨¼ö¼º
  • antimicrobial susceptibility test
    Ç×±ÕÁ¦°¨¼ö¼º°Ë»ç
  • gene
    À¯ÀüÀÚ
  • allelic gene
    ´ë¸³À¯ÀüÀÚ
  • regulator gene
    Á¶ÀýÀ¯ÀüÀÚ
  • structural gene
    ±¸Á¶À¯ÀüÀÚ
  • suicide gene
    ÀÚ»ìÀ¯ÀüÀÚ
  • supressor gene
    ¾ïÁ¦À¯ÀüÀÚ
  • tumor suppressor gene
    Á¾¾ç¾ïÁ¦À¯ÀüÀÚ
  • gene transfer
    À¯ÀüÀÚÀü´Þ
  • gene translocation
    À¯ÀüÀÚÀüÀ§
  • gene transfection
    1.À¯ÀüÀÚÀü´Þ°¨¿°, 2.À¯ÀüÀÚÇÙ³»ÁÖÀÔ
  • gene therapy
    À¯ÀüÀÚ¿ä¹ý
  • cancer
    ¾Ï
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • antimicrobial susceptibility
    Ç×±ÕÁ¦°¨¼ö¼º
  • antimicrobial susceptibility test
    Ç×±ÕÁ¦°¨¼ö¼º½ÃÇè
  • magnetic susceptibility artifact
    ÀÚ±âÈ­À²Àΰø¹°
  • colorimetric caries susceptibility test
    ¿ì½Ä°¨¼ö¼ººñ»ö½ÃÇè
  • disease susceptibility
    Áúº´°¨¼ö¼º
  • dynamic susceptibility contrast technique
    ¿ªµ¿ÀÚÈ­À²´ëÁ¶±â¹ý
  • susceptibility distortion
    ÀÚÈ­À²¿Ö°î, °¨¼ö¼º¿Ö°î
  • magnetic susceptibility proton relaxation enhancement
    ÀÚ±âÈ­À²¾ç¼ºÀÚÀÌ¿ÏÁõ°­
  • genetic susceptibility
    À¯ÀüÀÚ°¨¼ö¼º, À¯ÀüÀû°¨¼ö¼º
  • magnetic susceptibility gradient
    ÀÚ±âÈ­À²±â¿ï±â
  • susceptibility gradient
    °¨¼ö¼º±â¿ï±â
  • host susceptibility
    ¼÷ÁÖ°¨¼ö¼º
  • hypnotic susceptibility
    Ãָ鰨¼ö¼º
  • magnetic susceptibility
    ÀÚ±âÈ­À²
  • mass susceptibility
    Áú·®¹Î°¨µµ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • antifungal susceptibility testing
    Ç×Áø±Õ°¨¼ö¼º½ÃÇè
  • antimicrobial susceptibility
    Ç×±ÕÁ¦°¨¼ö¼º
  • antimicrobial susceptibility test
    Ç×±Õ¹°Áú °¨¼ö¼º(ù÷жڪòõÊïáôàõ)½ÃÇè.
  • antimicrobial susceptibility test
    Ç×±Õ¹°Áú °¨¼ö¼º(ù÷жڪòõÊïáôàõ)½ÃÇè.
  • antimicrobial susceptibility test
    Ç×±ÕÁ¦°¨¼ö¼º½ÃÇè
  • antimicrobial susceptibility testing
    Ç×±ÕÁ¦°¨¼ö¼º½ÃÇè¹ý
  • genetic susceptibility
    À¯ÀüÀû °¨¼ö¼º
  • genetic susceptibility
    À¯ÀüÀÚ°¨¼ö¼º
  • advanced cancer
    ÁøÇà¾Ï(òäú¼ ).
  • anal cancer
    Ç×¹®¾Ï(Ç×¹®¾Ï).
  • gastric cancer
    À§¾Ï(êÖ ).
  • gastric cancer
    À§¾Ï(À§¾Ï).
  • glandular cancer
    ¼±¾Ï(¼±¾Ï).
  • glottic cancer
    ¼º¹®¾Ï
  • polypoid cancer =fungoid c.
    Æú¸³¾ç¾Ï(¡­åÆäß)
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • antifungal susceptibility testing
    Ç×Áø±Õ°¨¼ö¼º½ÃÇè
  • antimicrobial susceptibility
    Ç×±ÕÁ¦°¨¼ö¼º
  • antimicrobial susceptibility test
    Ç×±Õ¹°Áú °¨¼ö¼º(ù÷жڪòõÊïáôàõ)½ÃÇè.
  • antimicrobial susceptibility test
    Ç×±ÕÁ¦°¨¼ö¼º½ÃÇè
  • antimicrobial susceptibility test
    Ç×±Õ¹°Áú °¨¼ö¼º(ù÷жڪòõÊïáôàõ)½ÃÇè.
  • antimicrobial susceptibility testing
    Ç×±ÕÁ¦°¨¼ö¼º½ÃÇè¹ý
  • atomic susceptibility
    ¿øÀÚÀÚÈ­À² (¡­í¸ûùëÒ).
  • colo(u)rimetric caries susceptibility test
    ¿ì½Ä°¨¼ö¼º ºñ»ö½ÃÇè(ó»ãÝÊïáô àõÝïßäãËúÐ).
  • disease susceptibility
    Áúº´°¨¼ö¼º
  • disk dilution susceptibility test
    µð½ºÅ©Èñ¼®°¨¼ö¼º½ÃÇè
  • dynamic susceptibility contrast technique
    ¿ªµ¿ ÀÚÈ­À² ´ëÁ¶ ±â¹ý
  • ether susceptibility
    ¿¡Å׸£°¨¼ö¼º (¿ÜÇǺ¸À¯¹ÙÀÌ·¯½ºÀÇ)
  • genetic susceptibility
    À¯ÀüÀÚ°¨¼ö¼º
  • genetic susceptibility
    À¯ÀüÀû °¨¼ö¼º
  • gradient echo technique magnetic susceptibility pro
    °æ»ç ¿¡ÄÚ¹ý ÀÚ±âÈ­À² ¾ç¼ºÀÚ ÀÌ¿Ï Áõ°­
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 8 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • Mutant gene
    µ¹¿¬º¯ÀÌÀ¯ÀüÀÚ
    [¿¾ ¿ë¾î] [µ¹¿¬]º¯ÀÌÀ¯ÀüÀÚ
  • Autosomal gene
    º¸Åë¿°»öüÀ¯ÀüÀÚ
    [¿¾ ¿ë¾î] »ó¿°»öüÀ¯ÀüÀÚ
  • Gonosomal gene
    ¼º¿°»öüÀ¯ÀüÀÚ
    [¿¾ ¿ë¾î] ¼º¿°»öüÀ¯ÀüÀÚ
  • Recessive autosomal gene
    ¿­¼ºº¸Åë¿°»öüÀ¯ÀüÀÚ
    [¿¾ ¿ë¾î] ¿­¼º»ó¿°»öüÀ¯ÀüÀÚ
  • Recessive gonosomal gene
    ¿­¼º¼º¿°»öüÀ¯ÀüÀÚ
    [¿¾ ¿ë¾î] ¿­¼º¼º¿°»öüÀ¯ÀüÀÚ
  • Dominant autosomal gene
    ¿ì¼ºº¸Åë¿°»öüÀ¯ÀüÀÚ
    [¿¾ ¿ë¾î] ¿ì¼º»ó¿°»öüÀ¯ÀüÀÚ
  • Dominant gonosomal gene
    ¿ì¼º¼º¿°»öüÀ¯ÀüÀÚ
    [¿¾ ¿ë¾î] ¿ì¼º¼º¿°»öüÀ¯ÀüÀÚ
  • Lethal gene
    Ä¡»çÀ¯ÀüÀÚ
    [¿¾ ¿ë¾î] Ä¡»çÀ¯ÀüÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • host susceptibility
    ¼÷ÁÖ°¨¼ö¼º
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • magnetic susceptibility
    ÀÚÈ­À²(í¸ûùëÒ)
  • cancer gene
    ¾ÏÀ¯ÀüÀÚ(äßë¶îîí­)
  • cancer
    ¾Ï(äß)
  • cancer biochemistry
    ¾Ï»ýÈ­ÇÐ(äßßæûùùÊ)
  • cancer-inducing virus
    ¹ß¾Ï(Û¡äß) ¹ÙÀÌ·¯½º
  • convergence theory of cancer
    "¾Ï ¼ö·Å·Ð(äßâ¥Ö°Öå),(ÔÒ) Greenstein hypothesis"
  • virus theory of cancer
    ¹ÙÀÌ·¯½º ¾Ï¹ß»ý·Ð(äßÛ¡ßæÖå)
  • abl gene
    abl À¯ÀüÀÚ(ë¶îîí­)
  • constitutive gene
    ±¸¼ºÀ¯ÀüÀÚ(ϰà÷ë¶îîí­)
  • controlling gene
    Á¶Àý À¯ÀüÀÚ(ðàï½ë¶îîí­)
  • c-src gene
    c-src À¯ÀüÀÚ(ë¶îîí­)
  • cytoplasmic gene
    ¼¼Æ÷Áú À¯ÀüÀÚ(á¬øàòõë¶îîí­)
  • D gene
    D À¯ÀüÀÚ(ë¶îîí­)
  • dispensable gene
    ºñÇʼö À¯ÀüÀÚ(Þªù±âÎë¶îîí­) (ÔÒ) nonessential gene
  • diversity gene
    ´Ù¾ç¼º À¯ÀüÀÚ(ÒýåÆàõë¶îîí­) = D gene
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • gene
    À¯ÀüÀÎÀÚ
  • alveolar cancer
    Æ÷»ó¾Ï
  • breast cancer
    À¯¹æ¾Ï
  • cancer
    ¾Ï
  • cancer in situ
    »óÇdz»¾Ï, ÀνÃÅõ¾Ï
  • early gastric cancer
    Á¶±âÀ§¾Ï
  • mammary cancer
    À¯¾Ï
  • ovarian cancer
    ³­¼Ò¾Ï
  • polypoid cancer
    Æú¸³¾ç¾Ï
  • primary cancer
    ¿ø¹ß¾Ï
  • radiation induced cancer
    ¹æ»ç¼±À¯¹ß¾Ï
  • skin cancer
    ÇǺξÏ
  • dynamic susceptibility contrast technique
    ¿ªµ¿ÀÚÈ­À²´ëÁ¶±â¹ý
  • gradient echo technique magnetic susceptibility proton relaxation enhancement
    °æ»ç¿¡ÄÚ¹ý±âÈ­À²¼ºÀÚÀÌ¿ÏÁõ°­
  • magnetic susceptibility
    ÀÚ±âÈ­À²
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
MSS Marshall-Smith syndrome; massage; Medical Superintendents' Society; Medicare Statistical System; men...
MSSG multiple sclerosis susceptibility gene
AFP Alpha(¥á) Feto-Protein [HP 1826, 1858, 1859, 2265]
  ; Oncofetal Antigens
 &nbs...
MCC mean corpuscular hemoglobin concentration; medial cell column; Medical Council of Canada; metacerebr...
CEA Carcino-Embryonic Antigen [HP 1825-6]
  ; Oncofetal Antigens
  ; Glycopro...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
DSC Dynamic susceptibility contrast
HGSHS:A Harvard Group Scale of Hypnotic Susceptibility, Form A
MHS Malignant hyperthermia susceptibility
S R)/susceptibility
SHSS:C Standford Hypnotic Susceptibility Scale, Form C
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • cancer suppressor gene
    ¾Ï ¾ïÁ¦ À¯ÀüÀÚ
  • antimicrobial susceptibility
    Ç×±ÕÁ¦ °¨¼ö¼º, Ç×±Õ °¨¼ö¼º
  • caries susceptibility test
    Ä¡¾Æ ¿ì½Ä °¨¼ö¼º ½ÃÇè
  • magnetic susceptibility artifact
    ÀÚ±âÈ­À² Àΰø¹°
  • magnetic susceptibility variation
    ÀÚ±âÈ­À² º¯ÀÌ
  • mass susceptibility
    Áú·® ¹Î°¨µµ
  • paramagnetic high susceptibility
    »óÀÚ¼º °íÀÚÈ­À²
  • paramagnetic susceptibility effect
    »óÀÚ¼º ÀÚ±âÈ­ È¿°ú
  • susceptibility test
    °¨¼ö¼º ½ÃÇè, °¨¼ö¼º Å×½ºÆ®, °¨¼ö¼º °Ë»ç
  • allelic gene
    ´ë¸³ À¯ÀüÀÚ
  • C-jun gene
    ¾¾-ÁØ À¯ÀüÀÚ
  • contiguous gene syndrome
    Á¢Ã˼º À¯ÀüÀÚ ÁõÈıº
  • control gene
    Á¦¾î À¯ÀüÀÚ
  • dominant gene
    ¿ì¼º À¯ÀüÀÚ
  • duplicate gene
    Áߺ¹ À¯Àü ÀÎÀÚ
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
cancer susceptibility gene tumour suppressor gene
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
BRCA1 breast cancer susceptibility gene This mutated (changed) version of the BRCA1 gene makes a person susceptible to developing breast cancer.
(12 Dec 1998)
breast cancer susceptibility genes Inherited factors that predispose to breast cancer. Put otherwise, these genes make one more susceptible to the disease and so increase the risk of developing breast cancer. Two of these genes, BRCA1 and BRCA2, have been identified (and prominently publicised). Several other genes (those for the Li-Fraumeni syndrome, Cowden disease, Muir-Torre syndrome, and ataxia-telangiectasia) are also known to predispose to breast cancer. However, since all of these known breast cancer susceptibility genes together do not account for more than a minor fraction (1/5th at most) of breast cancer that clusters in families, it is clear that more breast cancer genes remain to be discovered.
(12 Dec 1998)
cancer, breast, susceptibility genes Inherited factors that predispose to breast cancer. Put otherwise, these genes make one more susceptible to the disease and so increase the risk of developing breast cancer. Two of these genes, BRCA1 and BRCA2, have been identified (and prominently publicised). Several other genes (those for the Li-Fraumeni syndrome, Cowden disease, Muir-Torre syndrome, and ataxia-telangiectasia) are also known to predispose to breast cancer. However, since all of these known breast cancer susceptibility genes together do not account for more than a minor fraction (1/5th at most) of breast cancer that clusters in families, it is clear that more breast cancer genes remain to be discovered.
(12 Dec 1998)
genes, breast cancer susceptibility Inherited factors that predispose to breast cancer. Put otherwise, these genes make one more susceptible to the disease and so increase the risk of developing breast cancer. Two of these genes, BRCA1 and BRCA2, have been identified (and prominently publicised). Several other genes (those for the Li-Fraumeni syndrome, Cowden disease, Muir-Torre syndrome, and ataxia-telangiectasia) are also known to predispose to breast cancer. Howeverm, since all of these known breast cancer susceptibility genes together do not account for more than a minor fraction (1/5th at most) of breast cancer that clusters in families, it is clear that more breast cancer genes remain to be discovered. See related entries to: BRCA1; BRCA2; Breast cancer, familial.
(12 Dec 1998)
colourimetric caries susceptibility test A colourimetric test for determining dental caries activity or susceptibility based on the rate of acid production by acidogenic oral microorganisms (e.g., lactobacillus) in a glucose medium, using bromcresol green as the indicator, and producing a colour change from green to yellow.
Synonym: colourimetric caries susceptibility test.
(05 Mar 2000)
susceptibility Origin: Cf. F. Susceptibilite.
1. The state or quality of being susceptible; the capability of receiving impressions, or of being affected.
2. Specifically, capacity for deep feeling or emotional excitement; sensibility, in its broadest acceptation; impressibility; sensitiveness.
<physics> Magnetic susceptibility, the intensity of magnetization of a body placed in a uniform megnetic field of unit strength.
Synonym: Capability, sensibility, feeling, emotion.
Source: Websters Dictionary
(01 Mar 1998)
susceptibility testing The determination of the ability of an antibiotic to kill or inhibit the growth of bacteria.
(05 Mar 2000)
disease susceptibility A constitution or condition of the body which makes the tissues react in special ways to certain extrinsic stimuli and thus tends to make the individual more than usually susceptible to certain diseases.
(12 Dec 1998)
American Cancer Society <address, organisation>
American Cancer Society, National Headquarters, 1599 Clifton Road, NE, Atlanta, GA 30329 USA.
Tel: 00 1 404 320-3333
(05 Feb 1998)
bladder cancer The most common warning sign of bladder cancer is blood in the urine. The diagnosis of bladder cancer is supported by findings in the medical history and examination, blood, urine, and X-ray tests, and confirmed with a biopsy (usually during a cystoscope exam). Treatment of bladder cancer depends on the growth, size, and location of the tumour.
(12 Dec 1998)
bladder cancer risks Smoking is a major risk factor. Cigarette smokers develop bladder cancer 2-3 times more often than do nonsmokers. Quitting smoking reduces the risk of bladder cancer, lung cancer, several other types of cancer, and a number of other diseases as well. Workers in some occupations are at higher risk of developing bladder cancer because of exposure to carcinogens (cancer-causing substances) in the workplace. These workers include people in the rubber, chemical, and leather industries, as well as hairstylists, machinists, metal workers, printers, painters, textile workers, and truck drivers.
(12 Dec 1998)
bone cancer <oncology> A general term to imply malignant tumour growth in bone.
(27 Sep 1997)
bovine cancer eye A malignant squamous cell carcinoma of cattle, especially the Hereford breed, that originates in the conjunctival mucous membranes or the surrounding skin; it occurs principally in range cattle having unpigmented skin around the eye and living in regions of intense sunlight.
(05 Mar 2000)
breast cancer <oncology> The uncontrolled growth of malignant breast tissue.
Breast cancer is currently the most common cancer in women and the leading cause of cancer-related death in the 15-54 age group.
Strong risk factors include a prior history for breast cancer or a positive family history for breast cancer.
Early detection is possible through the use of monthly breast self-examination, annual clinical exams and mammography.
WWW: cancerNET document for patients
WWW: cancerNET document for clinicians
(05 Jan 1998)
buyo cheek cancer betel cancer
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • susceptibility
    °¨¼ö¼º
  • susceptibility
    °¨¼ö¼º(to);°¨Á¤
  • cancer
    ¾Ï; ¾ÏÁ¾; ÇØ¾Ç; ÆóÇØ
  • cancer
    ¾Ï;¾ÏÁ¾;¾Ç¼ºÁ¾¾ç;(»çȸÀÇ)º´Æó;°ÔÀÚ¸®;°ÅÇØ±Ã;°ÔÀÚ¸®¿¡ ž »ç¶÷;¾Ïó·³ Ä§ÇØÇÏ´Ù;cancered (n,vt,a);¾Ï¿¡ °É¸°
  • cancer stick
    ´ã¹è(cigarette)
  • gastric cancer
    À§¾Ï
  • Ir gene
    (»ýÈ­)IrÀ¯ÀüÀÚ(¸é¿ª ÀÀ´ä À¯ÀüÀÚ)
  • coat gene
    ÇǸ·À¯ÀüÀÚ
  • dominant gene
    (»ý)¿ì¼º À¯ÀüÀÚ
  • gene
    À¯Àü(ÀÎ)ÀÚ
  • gene bank
    À¯ÀüÀÚ ÀºÇà(À¯Àü ¹°ÁúÀ» »ýÁ¸½ÃŲ »óÅ·Πº¸Á¸ÇÏ´Â ½Ã¼³
  • gene deletion
    À¯ÀüÀÚ »èÁ¦(ºÒÇÊ¿äÇÑ À¯ÀüÀÚÀÇ Á¦°Å)
  • gene expression
    À¯ÀüÀÚ ¹ßÇö(À¯ÀüÀÚ Á¤º¸°¡ ƯÁ¤ ÇüÁú·Î¼­ ³ªÅ¸³ª±â)
  • gene insertion
    À¯ÀüÀÚ »ðÀÔ(ºüÁ®ÀÖ´Â À¯ÀüÀÚ¸¦ »ðÀÔÇϱâ)
  • gene manipulation
    À¯ÀüÀÚ Á¶ÀÛ(ÀÎÀ§ÀûÀ¸·Î À¯ÀüÀÚ¸¦ ¿Å±â°Å³ª ¿°»öü µîÀ» º¯È­½Ã۱â)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á